22nd Century Group, Inc. (Nasdaq: XXII) is a self-described leading agricultural biotechnology company focused on improving health and wellness through plant science.

22nd Century Group

Apizee provides secure real-time visual support services to enhance customer service interactions. This includes solutions for customer service, field service, video conferencing, and telehealth, focusing on optimizing operational efficiency and customer satisfaction.

Apizee

22nd Century Group is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology. 

GVB Biopharma is now a 22nd Century company.

Crede CG III LTD

22nd Century Group, Inc.

Today, 22nd Century Group, Inc. announced it has secured the consent of its senior lender under the terms of its Senior Secured Credit Facility for the previously announced sale of its GVB Biopharma hemp/cannabis operations.

Read the full press release here: https://lnkd.in/gmA5yG8v

Today, 22nd Century Group, Inc. announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer.

Read the full press release here: https://lnkd.in/gxEUPxkH

Today, 22nd Century Group, Inc. announced it has reached an agreement to sell the GVB Biopharma hemp/cannabis franchise.

Read the full press release here: https://lnkd.in/eP7aNkSc

Today, 22nd Century Group, Inc. announced that it has again expanded its VLN® retail presence with more than 500 additional locations across 11 states.

With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine content cigarettes can now be found at more than 5,100 store locations spanning 23 states, including the addition of Washington, Oregon, Kentucky, and Louisiana.

“The addition of over 500 new VLN® sales locations has propelled us beyond the noteworthy milestone of 5,100 stores. Our VLN® sales presence now extends to 23 states, making VLN® available in many of the top markets where smokers reside,” stated John Miller, interim Chief Executive Officer of 22nd Century Group, Inc.

Read the full press release here: https://lnkd.in/gk9ecvgM

Today, 22nd Century Group, Inc. reported results for the third quarter ended September 30, 2023, and provided an update on recent business highlights.

Read the full press release here: https://lnkd.in/e_t84Z4J

Today, 22nd Century Group announced that it supports the recent move by the US Food and Drug Administration to send final rules aimed at banning menthol in cigarettes and banning flavored cigars to the White House Office of Management and Budget for review, a key regulatory step toward the rules becoming federal policy.

“The FDA has taken a significant step forward to enact federal enforcement on these important public health policies,” said John Miller, Interim Chief Executive Officer of 22nd Century Group. “The FDA has closely studied these issues for years, accumulating a wealth of scientific and clinical research data in support of these advances. Submission of the FDA’s proposals to the OMB is a key step ahead of publishing the final rules, which we believe could be the most transformative proactive public health policies of a generation. We are eager to see the final rules, and how FDA proposes to handle products with modified risk designations, which are designed to reduce the harms associated with smoking.”

Read the full press release here: https://lnkd.in/gn8w9N6t

Today, 22nd Century Group $XXII announced that it has reduced the outstanding principle of its Senior Secured Credit Facility from approximately $22.1 million to approximately $14.0 million as part of an amendment and waiver process with its lenders.

Read the full press release here: https://lnkd.in/gt_ztNTB

Today, 22nd Century announced a proposed public offering.

Read the full press release here: https://lnkd.in/gnpcRhr9

Today, 22nd Century Group, Inc. announced its FDA authorized VLN® reduced nicotine content cigarettes designed specifically to promote tobacco harm reduction are now available at more than 1,200 drug store locations across Texas, Florida, Illinois, North Carolina, and Georgia beginning in September.

Read the full press release here: https://lnkd.in/dhK-ja2Y

Today, 22nd Century Group, Inc. announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets.

The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements, alternate financing strategies, and other options.

Read the full press release here: https://lnkd.in/gFMd7Xci

Metric
Company Name	22	Apizee
Symbol
MSH ID	COM:XXIICENTURY	COM:APIZEE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services
Industry	Agricultural Biotechnology	Technology
Country	US	FR
Stage		Non Equity Assistance
Employee Count
Website	xxiicentury.com	apizee.com
LinkedIn	22nd-century-group	apizee
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		297.48K
Web Traffic Growth		0.66
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

XXII

COM:XXIICENTURY

22nd Century Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue